cbd adalah penyakit

CBD dianggap WHO telah banyak berperan penting dalam terapi kesehatan selama beberapa tahun terakhir. Senyawa ini juga dimanfaatkan dalam industri yang bernilai miliaran dolar AS.

Penelitian terhadap kegunaan ganja di bidang kedokteran dilakukan karena tanaman ini memiliki 113 senyawa kimia berbeda yang dikenal sebagai cannabinoid.

Dua senyawa pada ganja yang dinilai berpotensi menjadi obat adalah Cannabidiol (CBD) dan delta-9-tetrahydrocannabinol (THC). CBD dan THC adalah senyawa ganja yang berpotensi sebagai obat medis, terutama untuk gangguan mental seperti stres, kecemasan, hingga insomnia.

Efek CBD dan THC saat Masuk Tubuh

Keputusan Komisi Narkotika PBB itu keluar setelah CND mempertimbangankan rekomendasi WHO. Dari 53 negara anggota CND yang mengikuti pemungutan suara, 27 mendukung pencabutan ganja dari Daftar IV Konvensi Tunggal Narkotika 1961, 25 menolak, dan satu lainnya abstain.

Selain bersumber dari ganja, CBD bisa pula diekstraksi dari rami. Hasil ekstraksi rami mengandung senyawa THC lebih rendah.

Perbedaan Senyawa Ganja CBD dan THC

Senyawa CBD dalam ganja sudah ditemukan sejak sekitar tahun 1940-an. Namun baru belakangan ini, CBD mulai diperhatikan untuk keperluan pengobatan.

Semua tahu, ganja bisa memicu perasaan euforia. Ini karena otak melepas hormon dopamin yang bertanggung jawa memuculkan perasaan senang. Dan, senyawa THC dalam ganja jadi pemicunya.

§ The compound 4-CCB has been identified in Europe since 2016 when samples were intercepted as synthetic cannabinoids; 4-CCB is chemically related to other indazole-based synthetic cannabinoids, known as NACA derivatives, which are found in other synthetic cannabinoid clusters reported in the United States.

* CBD is used in treating spasticity from multiple sclerosis and Dravet syndrome, a severe form of childhood epilepsy, for which it has shown efficacy.

See also  cbd pharmacy medical centre

No conflicts of interest were reported.

Corresponding author: Roberta Z Horth, [email protected], 801-538-9465.

References

1 Epidemic Intelligence Service, CDC; 2 Utah Department of Health, Salt Lake City, Utah; 3 Utah Poison Control Center, Salt Lake City, Utah; 4 Utah Department of Health, Public Health Laboratory, Taylorsville, Utah; 5 Utah Department of Public Safety, Bureau of Forensic Services, Taylorsville, Utah; 6 Utah State Bureau of Investigation, Salt Lake City, Utah; 7 Utah Department of Public Safety, Statewide Information and Analysis Center, Sandy, Utah; 8 Salt Lake County Health Department, Salt Lake City, Utah; 9 Utah County Health Department, Provo, Utah.

On December 8, 2017, the Utah Poison Control Center (UPCC) notified the Utah Department of Health (UDOH) of reports of emergency department visits associated with reported exposure to products labeled as CBD (cannabidiol), a nonpsychoactive compound derived from Cannabis sativa, the marijuana plant. Five patients experienced adverse reactions, including altered mental status, seizures, confusion, loss of consciousness, and hallucinations. These reactions were inconsistent with known CBD effects (1), which prompted concern for potential adulteration with a synthetic cannabinoid (2). CBD is being studied as a treatment for several health conditions* (3); however, the Food and Drug Administration has not approved any CBD product for the treatment of any condition, and the U.S. Department of Justice Drug Enforcement Administration considers CBD as a Schedule I drug. † Sale of CBD is currently illegal in Utah, although CBD is readily available online and in shops.

By the end of January 2018, suspected cases were identified in 52 persons. Nine product samples (including one unopened product purchased by investigators from a store and brand reported by a patient) were found to contain a synthetic cannabinoid, 4-cyano CUMYL-BUTINACA (4-CCB), but no CBD. ¶ Eight of the tested products were branded as “Yolo CBD oil” and indicated no information about the manufacturer or ingredients. Blood samples from four of five persons were positive for 4-CCB. Press releases were distributed to media outlets December 19–21, 2017, with a warning regarding the dangers of using the counterfeit product; information with a description of the product and associated symptoms was disseminated to health care providers and law enforcement. The number of reported cases peaked during this outreach and dropped shortly thereafter. Thirty-four suspected cases were reclassified as confirmed if the person reported use of a Yolo product or laboratory testing found 4-CCB. Approximately one quarter of persons were aged <18 years, nearly three fourths had vaped the CBD product, and approximately 60% were seen at an emergency department ( Table). The top three symptoms experienced were altered mental status, nausea or vomiting, and seizures or shaking. Rapid identification and a coordinated response among state and local agencies contributed to control of the outbreak. This investigation highlights the hazards of consuming unregulated products labeled as CBD. States could consider regulating products labeled as CBD and establishing surveillance systems for illness associated with products labeled as CBD to minimize the risk for recurrences of this emerging public health threat (5).

See also  green roads cbd vape oil

Conflict of Interest

¶ Search terms included CBD-associated slang and brands. Search terms excluded symptoms because they were insufficiently specific.

† A Schedule I drug, defined by the U.S. Department of Justice Drug Enforcement Administration, is a drug with no currently accepted medical use and a high potential for abuse.